Close Menu

NEW YORK (GenomeWeb) – Biocept said today that it has reached an agreement for the validation and potential adoption of its Target Selector liquid biopsy kits in Agiomix's lab in the United Arab Emirates lab.

Agiomix will test the kits to ensure comparability of results achieved in Biocept's San Diego CLIA-certified, CAP-accredited facility. Subject to that validation, Agiomix would then purchase the kits for use in its genomics test services, analyzing samples received from the Middle East, Africa, and Asia.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.